Study population
bleeding, pneumonia, fever, cancer, pulmonary distress
CANCER, BLEEDING, PNEUMONIA
Ambulatory or hospitalized adults (≥ 18 years old) with moderate to severe COVID-19 confirmed by a positive polymerase chain reaction (PCR) for up to 14 days prior to randomization were eligible for the study. Moderate cases were defined as patients with fever and/or respiratory symptoms and one of the following signs of pulmonary distress: respiratory rate > 22/min, oxygen saturation ≤ 95% or radiological findings of pneumonia. Severe cases were patients that met any of the following criteria: respiratory rate ≥ 30/min, oxygen saturation ≤ 93% at rest or a PaOPatients with a high bleeding risk, platelet count < 90.000/µL, active cancer, any medical condition that required an anticoagulation, a contraindication for the use of rivaroxaban or heparin, an estimated glomerular filtration rate (eGRF) less than 30 mL/min/1.73 m